$ABUS MRNA motivation to settle $MRNA ABUS Anticipating that abus will receive due reward rather than $MRNA steam rolling over the small biotech with fundamental technology to their pipeline during the race for cv vaccination. The question is more about how valuable is it to avoid further public scrutiny and risk for - -unpredictable loss both tangible and intangible - - delayed product development / go to market of pipeline - -negative impact to operations, active programs (clinical trials) - -poor employee morale - unplanned resource allocation on conflicting priorities - reduced investor perception and market cap. This seems like a no brainer in terms of next steps for Moderna and there are only a few likely options.
  • 3